Karyopharm TherapeuticsKPTI
About: Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
Employees: 279
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
512% more call options, than puts
Call options by funds: $581K | Put options by funds: $95K
5.35% less ownership
Funds ownership: 48.27% [Q4 2024] → 42.92% (-5.35%) [Q1 2025]
46% less funds holding
Funds holding: 87 [Q4 2024] → 47 (-40) [Q1 2025]
67% less capital invested
Capital invested by funds: $41.2M [Q4 2024] → $13.7M (-$27.5M) [Q1 2025]
95% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 42
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 45
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
HC Wainwright & Co. Robert Burns | 493%upside $27 | Buy Assumed | 11 Jul 2025 |
RBC Capital Brian Abrahams | 625%upside $33 | Outperform Maintained | 13 May 2025 |
Barclays Peter Lawson | 120%upside $10 | Overweight Maintained | 13 May 2025 |
Baird Michael Ulz | 823%upside $42 | Outperform Maintained | 13 May 2025 |
Financial journalist opinion
